Published in Mol Med on June 01, 1999
Tumor necrosis factor-α signaling maintains the ability of cortical synapses to express synaptic scaling. J Neurosci (2010) 1.23
Intrauterine infection/inflammation during pregnancy and offspring brain damages: possible mechanisms involved. Reprod Biol Endocrinol (2004) 0.99
Heterogeneity of microglia and TNF signaling as determinants for neuronal death or survival. Neurotoxicology (2009) 0.98
Targeting TNF-alpha receptors for neurotherapeutics. Trends Neurosci (2008) 0.97
Reduced oxidative stress promotes NF-kappaB-mediated neuroprotective gene expression after transient focal cerebral ischemia: lymphocytotrophic cytokines and antiapoptotic factors. J Cereb Blood Flow Metab (2006) 0.95
Association of tumor necrosis factor alpha gene polymorphism G-308A with pseudoexfoliative glaucoma in the Pakistani population. Mol Vis (2009) 0.90
Polymorphism in the TNF-α(-863) locus associated with reduced risk of primary open angle glaucoma. Mol Vis (2012) 0.89
MyD88 and Src are differentially regulated in Kupffer cells of males and proestrus females following hypoxia. Mol Med (2006) 0.81
Neuroprotective effect of endogenous cannabinoids on ischemic brain injury induced by the excess microglia-mediated inflammation. Am J Transl Res (2016) 0.77
Temporal regulation of apoptotic and anti-apoptotic molecules after middle cerebral artery occlusion followed by reperfusion. Mol Neurobiol (2013) 0.77
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res (1983) 124.30
The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol (1996) 22.30
Apoptosis in the pathogenesis and treatment of disease. Science (1995) 20.24
Function and activation of NF-kappa B in the immune system. Annu Rev Immunol (1994) 17.04
An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science (1996) 13.87
Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science (1996) 12.23
NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (1998) 11.70
TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science (1996) 11.29
Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell (1996) 9.68
NF-kappa B and Rel: participants in a multiform transcriptional regulatory system. Int Rev Cytol (1993) 7.42
Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci U S A (1997) 4.07
Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke (1997) 3.26
Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J (1996) 2.68
Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science (1996) 2.52
Tumor necrosis factor-alpha expression in ischemic neurons. Stroke (1994) 2.37
Constitutive NF-kappa B activity in neurons. Mol Cell Biol (1994) 1.96
Measurement of striatal H2O2 by microdialysis following global forebrain ischemia and reperfusion in the rat: correlation with the cytotoxic potential of H2O2 in vitro. Brain Res (1995) 1.93
Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci U S A (1997) 1.77
Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis. J Cell Biol (1996) 1.71
Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. J Neurosci Res (1997) 1.54
Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. Mol Med (1997) 1.51
Tumor necrosis factor is a brain damaging cytokine in cerebral ischemia. Shock (1997) 1.48
A brain-specific transcription activator. Neuron (1989) 1.41
Brain synapses contain inducible forms of the transcription factor NF-kappa B. Mech Dev (1993) 1.40
Stimulation of ionotropic glutamate receptors activates transcription factor NF-kappa B in primary neurons. Proc Natl Acad Sci U S A (1995) 1.35
Correlation between the anticellular and DNA fragmenting activities of tumor necrosis factor. Cancer Res (1988) 1.31
Inhibition of tumor necrosis factor and amelioration of brain infarction in mice. J Cereb Blood Flow Metab (1997) 1.23
Circulating antibody against tumor necrosis factor-alpha protects rat brain from reperfusion injury. J Cereb Blood Flow Metab (1998) 1.22
Global ischemia activates nuclear factor-kappa B in forebrain neurons of rats. Stroke (1997) 1.19
Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid beta-peptide toxicity. J Neurochem (1996) 1.19
Exposure to hydrogen peroxide induces cell death via apoptosis in cultured rat cortical neurons. Neuroreport (1994) 1.16
Cerebral hypoxia-ischemia stimulates cytokine gene expression in perinatal rats. Stroke (1995) 1.15
Tumor necrosis factor alpha-induced apoptosis in human neuronal cells: protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA. Mol Cell Biol (1995) 1.14
Inhibition of tumor necrosis factor-alpha reduces focal cerebral ischemic injury in the spontaneously hypertensive rat. Neurosci Lett (1996) 1.07
Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A (1995) 1.07
High constitutive NF-kappaB activity mediates resistance to oxidative stress in neuronal cells. J Neurosci (1998) 1.04
Expression of tumor necrosis factor alpha after focal cerebral ischaemia in the rat. Neuroscience (1996) 1.01
Induction of tumor necrosis factor-alpha in the mouse hippocampus following transient forebrain ischemia. J Cereb Blood Flow Metab (1997) 1.00
Alteration of transcription factor binding activities in the ischemic rat brain. Biochem Biophys Res Commun (1995) 1.00
Ceramide-induced nuclear translocation of NF-kappa B is a potential mediator of the apoptotic response to TNF-alpha in murine clonal osteoblasts. Bone (1996) 0.98
Cytokine-induced programmed death of cultured sympathetic neurons. Neuron (1993) 0.87
Interrelated effects of tumor necrosis factor and interleukin 1 on cell viability. Immunobiology (1988) 0.85
The role of polypeptide growth factors in recovery from stroke. Adv Neurol (1997) 0.84
HMG-1 as a late mediator of endotoxin lethality in mice. Science (1999) 17.72
Shock and tissue injury induced by recombinant human cachectin. Science (1986) 16.24
Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature (2000) 11.49
High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med (2000) 7.38
MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature (1993) 5.60
HMG-1 as a mediator of acute lung inflammation. J Immunol (2000) 4.78
Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med (1989) 4.66
Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet (1987) 4.18
Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet (1988) 3.30
Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest (1991) 3.00
Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med (2004) 2.94
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene (2010) 2.91
HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med (2001) 2.80
Macrophage inflammatory protein 1 modulates macrophage function. J Immunol (1992) 2.66
High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum (2002) 2.45
Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery (1999) 2.44
Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum (2003) 2.26
Cholinergic control of inflammation. J Intern Med (2009) 2.12
The pulse of inflammation: heart rate variability, the cholinergic anti-inflammatory pathway and implications for therapy. J Intern Med (2011) 2.08
Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Auton Neurosci (2000) 2.06
High mobility group 1 B-box mediates activation of human endothelium. J Intern Med (2003) 2.00
Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol (1989) 1.99
Evidence for the involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat. Pain (1997) 1.90
Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120. Brain Res (2000) 1.83
Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock. Lancet (1999) 1.71
Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: a counterregulatory mechanism that restrains the immune response. J Exp Med (1997) 1.70
Malaria-specific metabolite hemozoin mediates the release of several potent endogenous pyrogens (TNF, MIP-1 alpha, and MIP-1 beta) in vitro, and altered thermoregulation in vivo. J Inflamm (1995) 1.62
Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J Exp Med (1996) 1.61
Neural regulators of innate immune responses and inflammation. Cell Mol Life Sci (2004) 1.60
Cholinergic agonists attenuate renal ischemia-reperfusion injury in rats. Kidney Int (2008) 1.55
Cytokine production in a model of wound healing: the appearance of MIP-1, MIP-2, cachectin/TNF and IL-1. Cytokine (1990) 1.53
Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. Mol Med (1997) 1.51
Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet (1990) 1.50
Cachectin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential. J Exp Med (1986) 1.49
Tumor necrosis factor is a brain damaging cytokine in cerebral ischemia. Shock (1997) 1.48
Autonomic neural regulation of immunity. J Intern Med (2005) 1.44
Fetuin (alpha2-HS-glycoprotein) opsonizes cationic macrophagedeactivating molecules. Proc Natl Acad Sci U S A (1998) 1.42
HMG-1 rediscovered as a cytokine. Shock (2001) 1.37
Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci U S A (1991) 1.29
Controlling inflammation: the cholinergic anti-inflammatory pathway. Biochem Soc Trans (2006) 1.28
Peripheral blood leukocyte kinetics following in vivo lipopolysaccharide (LPS) administration to normal human subjects. Influence of elicited hormones and cytokines. Ann Surg (1989) 1.27
CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Proc Natl Acad Sci U S A (1996) 1.22
The critical role of p38 MAP kinase in T cell HIV-1 replication. Mol Med (1997) 1.20
Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scand J Immunol (2004) 1.19
Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-alpha) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats. Clin Exp Immunol (1999) 1.18
Regulation of macrophage activation and inflammation by spermine: a new chapter in an old story. Crit Care Med (2000) 1.18
Subacute paraparesis induced by venous thrombosis of a spinal angiolipoma: a case report. Spine (Phila Pa 1976) (1997) 1.18
Pathogenic hantaviruses selectively inhibit beta3 integrin directed endothelial cell migration. Arch Virol (2002) 1.17
Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to carrageenan. Shock (2001) 1.17
Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res (2001) 1.16
VP4 differentially regulates TRAF2 signaling, disengaging JNK activation while directing NF-kappa B to effect rotavirus-specific cellular responses. J Biol Chem (2001) 1.12
Cerebral ischemia enhances polyamine oxidation: identification of enzymatically formed 3-aminopropanal as an endogenous mediator of neuronal and glial cell death. J Exp Med (1998) 1.10
Whole blood cytokine attenuation by cholinergic agonists ex vivo and relationship to vagus nerve activity in rheumatoid arthritis. J Intern Med (2010) 1.08
Prevention and treatment of experimental autoimmune encephalomyelitis by CNI-1493, a macrophage-deactivating agent. J Immunol (1998) 1.07
Lipopolysaccharide-induced cytokine cascade and lethality in LT alpha/TNF alpha-deficient mice. Mol Med (1997) 1.01
The physiologic consequences of macrophage pacification during severe acute pancreatitis. Shock (1998) 0.99
Fetuin protects the fetus from TNF. Lancet (1997) 0.98
Spermine inhibition of monocyte activation and inflammation. Mol Med (1999) 0.98
Evidence of a central role for p38 map kinase induction of tumor necrosis factor alpha in pancreatitis-associated pulmonary injury. Surgery (1999) 0.94
Tumor necrosis factor-enhanced leukotriene B4 generation and chemotaxis in human neutrophils. Arch Surg (1988) 0.93
Inhibition of p38 mitogen activate kinase attenuates the severity of pancreatitis-induced adult respiratory distress syndrome. Crit Care Med (2000) 0.91
Extremity amino acid metabolism during starvation and intravenous refeeding in humans. Am J Physiol (1986) 0.90
HMGB1 mediates splenomegaly and expansion of splenic CD11b+ Ly-6C(high) inflammatory monocytes in murine sepsis survivors. J Intern Med (2013) 0.89
Cerebroprotective effects of aminoguanidine in a rodent model of stroke. Stroke (1996) 0.89
Abruptio placentae associated with cocaine use. Am J Obstet Gynecol (1983) 0.88
Differential neutrophil activation before and after endotoxin infusion in enterally versus parenterally fed volunteers. Surg Gynecol Obstet (1988) 0.88
Comparison of numerical and phenotypic leukocyte changes during constant hydrocortisone infusion in normal humans with those in thermally injured patients. Surg Gynecol Obstet (1987) 0.87
High mobility group box 1 (HMGB1) protein: possible amplification signal in the pathogenesis of falciparum malaria. Trans R Soc Trop Med Hyg (2005) 0.87
Macrophage pacification reduces rodent pancreatitis-induced hepatocellular injury through down-regulation of hepatic tumor necrosis factor alpha and interleukin-1beta. Hepatology (1998) 0.87
Cachectin: a pluripotent hormone released during the host response to invasion. Recent Prog Horm Res (1987) 0.85
Correction of lower extremity deep venous incompetence by ablation of superficial venous reflux. Ann Vasc Surg (1996) 0.85
Targeted suppression of cytokine production in monocytes but not in T lymphocytes by a tetravalent guanylhydrazone (CNI-1493). J Infect Dis (1997) 0.84
Increased expression of estrogen receptor beta in human uterine smooth muscle at term. Eur J Endocrinol (2000) 0.84
Influence of substrate background on peripheral tissue responses to growth hormone. J Surg Res (1988) 0.82
HMGB1, a pro-inflammatory cytokine of clinical interest: introduction. J Intern Med (2004) 0.82
The functions of HMGB1 depend on molecular localization and post-translational modifications. J Intern Med (2014) 0.81
Regulation of total mitochondrial Ca2+ in perfused liver is independent of the permeability transition pore. Am J Physiol (1999) 0.81
Specific inhibition of macrophage-derived proinflammatory cytokine synthesis with a tetravalent guanylhydrazone CNI-1493 accelerates early islet graft function posttransplant. Transplant Proc (1998) 0.81
Dynamics of early synovial cytokine expression in rodent collagen-induced arthritis : a therapeutic study using a macrophage-deactivating compound. Am J Pathol (2001) 0.81
Hypophysectomy, high tumor necrosis factor levels, and hemoglobinemia in lethal endotoxemic shock. Shock (1998) 0.81
Tolerance to shock: an exploration of mechanism. Ann Surg (1999) 0.81
Suppression of macrophage activation with CNI-1493 increases survival in infant rats with systemic Haemophilus influenzae infection. Infect Immun (2000) 0.80
Length of postpartum anestrus in goats in subtropical Mexico: effect of season of parturition and duration of nursing. Theriogenology (1998) 0.80
Submaximal exercise during intravenous hyperalimentation of depleted subjects. Ann Surg (1988) 0.80
Occupational asthma caused by fish inhalation. Allergy (1997) 0.79
Recombinant growth hormone enhances muscle myosin heavy-chain mRNA accumulation and amino acid accrual in humans. Proc Natl Acad Sci U S A (1989) 0.79
Progestin represses human connexin43 gene expression similarly in primary cultures of myometrial and uterine leiomyoma cells. Biol Reprod (1996) 0.78
The effect of starvation and total parenteral nutrition on skeletal muscle amino acid content and membrane potential difference in normal man. Surg Gynecol Obstet (1988) 0.78
The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacy. Proc Natl Acad Sci U S A (1998) 0.77
Prevention of lethality and suppression of proinflammatory cytokines in experimental septic shock by microencapsulated CNI-1493. J Interferon Cytokine Res (1999) 0.77
CNI-1493 attenuates hemodynamic and pro-inflammatory responses to LPS. Shock (1998) 0.77
Increased energy expenditure in a patient with diencephalic syndrome. J Pediatr (1993) 0.77
Molecular basis of applied biological therapeutics. J Intern Med (2011) 0.76
CNI-1493 prolongs survival and reduces myocyte loss, apoptosis, and inflammation during rat cardiac allograft rejection. J Cardiovasc Pharmacol (1998) 0.76
Signet ring carcinoma of the pancreas, a rare variant with very high CEA values. Immunohistologic comparison with adenocarcinoma. Dig Dis Sci (1984) 0.76
Introduction: The first Merinoff Symposium, 'Systemic Lupus: Bringing Science to the Patient'. J Intern Med (2009) 0.75